Alzheimer's disease drug development pipeline: 2024

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2024-04-24 DOI:10.1002/trc2.12465

Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Feixiong Cheng

{"title":"Alzheimer's disease drug development pipeline: 2024","authors":"Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Feixiong Cheng","doi":"10.1002/trc2.12465","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We interrogated clinicaltrials.gov including all clinical trials assessing pharmaceutical therapies for AD active in on January 1, 2024. We used the Common Alzheimer's Disease Research Ontology (CADRO) to classify the targets of therapies in the pipeline.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>There are 164 trials assessing 127 drugs across the 2024 AD pipeline. There were 48 trials in Phase 3 testing 32 drugs, 90 trials in Phase 2 assessing 81 drugs, and 26 trials in Phase 1 testing 25 agents. Of the 164 trials, 34% (<i>N</i> = 56) assess disease-modifying biological agents, 41% (<i>N</i> = 68) test disease-modifying small molecule drugs, 10% (<i>N</i> = 17) evaluate cognitive enhancing agents, and 14% (<i>N</i> = 23) test drugs for the treatment of neuropsychiatric symptoms.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40).</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>In the 2024 Alzheimer's disease drug development pipeline, there are 164 clinical trials assessing 127 drugs.</li>\n \n <li>The 2024 Alzheimer's disease drug development pipeline has contracted compared to the 2023 Alzheimer pipeline with fewer trials, fewer drugs, and fewer new chemical entities.</li>\n \n <li>Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity.</li>\n \n <li>The total development time for a potential Alzheimer's disease therapy to progress from nonclinical studies to FDA review is approximately 13 years.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"10 2","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.12465","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.12465","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.

METHODS

We interrogated clinicaltrials.gov including all clinical trials assessing pharmaceutical therapies for AD active in on January 1, 2024. We used the Common Alzheimer's Disease Research Ontology (CADRO) to classify the targets of therapies in the pipeline.

RESULTS

There are 164 trials assessing 127 drugs across the 2024 AD pipeline. There were 48 trials in Phase 3 testing 32 drugs, 90 trials in Phase 2 assessing 81 drugs, and 26 trials in Phase 1 testing 25 agents. Of the 164 trials, 34% (N = 56) assess disease-modifying biological agents, 41% (N = 68) test disease-modifying small molecule drugs, 10% (N = 17) evaluate cognitive enhancing agents, and 14% (N = 23) test drugs for the treatment of neuropsychiatric symptoms.

DISCUSSION

Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40).

Highlights

In the 2024 Alzheimer's disease drug development pipeline, there are 164 clinical trials assessing 127 drugs.
The 2024 Alzheimer's disease drug development pipeline has contracted compared to the 2023 Alzheimer pipeline with fewer trials, fewer drugs, and fewer new chemical entities.
Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity.
The total development time for a potential Alzheimer's disease therapy to progress from nonclinical studies to FDA review is approximately 13 years.

Abstract Image

查看原文本刊更多论文

阿尔茨海默病药物开发管线：2024 年

引言我们需要新的疗法来预防或延缓阿尔茨海默病（AD）症状的出现、减缓病情发展或改善认知和行为症状。方法我们查询了 clinicaltrials.gov，其中包括评估 2024 年 1 月 1 日活跃的阿尔茨海默病药物疗法的所有临床试验。我们使用通用阿尔茨海默病研究本体（CADRO）对在研疗法的靶点进行了分类。结果 2024 年阿兹海默症治疗管线中共有 164 项试验，评估了 127 种药物。其中 48 项试验处于 3 期，测试 32 种药物；90 项试验处于 2 期，评估 81 种药物；26 项试验处于 1 期，测试 25 种药物。在这164项试验中，34%（56项）评估了改变疾病的生物制剂，41%（68项）测试了改变疾病的小分子药物，10%（17项）评估了增强认知能力的药物，14%（23项）测试了治疗神经精神症状的药物。讨论与 2023 年的管线相比，试验数量减少（164 对 187），药物数量减少（127 对 141），新化学实体减少（88 对 101），重新使用的药物数量相似（39 对 40）。亮点在 2024 年阿尔茨海默病药物开发管线中，共有 164 项临床试验，评估了 127 种药物。与2023年的阿尔茨海默氏症药物开发管线相比，2024年的阿尔茨海默氏症药物开发管线有所收缩，试验数量、药物数量和新化学实体数量都有所减少。阿尔茨海默病药物开发管线中的药物针对一系列靶点；最常见的靶点过程包括神经递质受体、炎症、淀粉样蛋白和突触可塑性。一种潜在的阿尔茨海默病治疗药物从非临床研究到通过美国食品及药物管理局（FDA）审查的总研发时间约为 13 年。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.